Key clinical point: For patients with COPD or asthma, inhaled corticosteroids (ICS) do not reduce the risk of COVID-19–related death.
Major finding: Patients with COPD who were prescribed ICS had an increased risk of COVID-19–related death, compared with COPD patients who were prescribed LABA + LAMA (aHR, 1.39; 95% CI, 1.10-1.76).
Study details: An observational study involving 148,557 people with COPD and 818,490 people with asthma.
Disclosures: The study was funded by the U.K. Medical Research Council. The investigators reported additional relationships with the Wellcome Trust, the Good Thinking Foundation, the Laura and John Arnold Foundation, and others. Dr. Conroy reported no conflicts of interest.
Schultze et al. Lancet Respir Med. 2020 Sep 24. doi: 10.1016/ S2213-2600(20)30415-X.